Furthermore, Itraconazole, previously discovered as an antifungal agent, has been found to have anticancer action by inhibiting mTOR signaling (118), and a recent clinical trial conducted in BCC patients have shown encouraging effectiveness (119). Here, MTOR is linked to skin basal cell carcinoma.